Skip Navigation
 
 
 
 xxx
 
 
 
 
 
 
 
 
 
Print This Page
Share this page: More
 

Information for Insurers

Information for Insurers


MARYLAND STATE SENATE BILL 137/HB45
EFFECTIVE JANUARY 1, 1999

MARYLAND STATE SENATE BILL 101/HB 109 EFFECTIVE JULY 1, 1999

Update on Medicare National Coverage of
Routine Costs of a Clinical Trial
– Effective September 19, 2000

The Health Care Financing Administration announced the Final National Coverage Decision regarding Medicare coverage of items and services for clinical trials. Effective September 19, 2000, Medicare coverage is available for "…routine costs of qualifying clinical trials… as well as reasonable and necessary items and services used to diagnose and treat complications arising from participation in all clinical trials." The announcement details items that are still excluded from coverage (including investigational new drugs) and the three requirements a clinical trial must meet before Medicare coverage may be provided. Please refer to the CMS/Centers for Medicare & Medicaid Services for information concerning the important details regarding Medicare coverage.

Health Insurance - Medical Clinical Trials – Coverage

The Governor signed into law SB 101/HB109 which extends insurance coverage to Phase I trials of life threatening conditions. The coverage must be provided with new insurance policies issued on or after July 1, 1999. All other policies must make the change to include coverage by January 1, 2000. The conditions applicable to Phase II, III, or IV clinical trials remain in effect as noted below.

Maryland State Senate Bill 137/HB45 requires insurers, nonprofit health service plans, and HMOs (carriers) to provide coverage for patient costs incurred as a result of treatment provided in a clinical trial for: (1) a life-threatening condition; or (2) prevention, early detection, and treatment studies on cancer. The coverage must be provided if: (1) the treatment is for all four phases of clinical trial for cancer, or the treatment is for Phases II, III, or IV clinical trials for other life-threatening conditions; and (2) the treatment meets other specific criteria in the law. In conjunction with the above-mentioned coverage, a carrier must provide coverage for costs incurred by patients for FDA-approved drugs and devices, whether or not the FDA has approved the drug or device for treating the enrollee’s particular condition. Coverage does not extend to the cost of investigational new drugs. The requirement to provide coverage under the Act does not apply to Medicaid programs. This web site has been developed to comply with the provisions of the Act.

The list of protocols provided on this site are, to the best of our knowledge, those approved trials that meet the provisions of the law. The list indicates the phase for which the trial is approved, the entity that approved the trial for conduct at Hopkins, the disease the investigational therapy is intended to treat, and the estimated number of patients at Hopkins who could be enrolled in the trial. Additions and deletions will be made as new trials are approved or trials are completed.

Questions concerning the list provided for insurers may be directed by E-mail to the Johns Hopkins Medicine Institutional Review Board (JHM-IRB) at jhmirb@jhmi.edu.

 Protocol List:

Revised:  July 2008

20030481 RPN Number entitled: " A Randomized Phase II Trial of EPOCH Given Either Concurrently or Sequentially with Rituximab in Patients with Intermediate- or High-Grade HIV-Associated B-Cell Non-Hodgkin's Lymphoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 6
20031167 RPN Number entitled: " A Phase I, Dose-Rising Study of AMD11070 in HIV-Seronegative Men to Assess the Safety and Pharmacokinectics after Single or Multiple Doses ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 42
20040310 RPN Number entitled: " Suppressive Long-Term Antiviral Management of Hepatitis C Virus (HCV) and HIV-1 Coinfected Subjects (SLAM-C), dated 01/08/04. ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 180
00-02-08-01 RPN Number entitled: " Novel Tuberculosis Prevention Regimens for HIV Infected Adults ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 2350
02-01-17-01 RPN Number entitled: " JOSTENT Coronary Stent Graft Device (HDE) ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 9
03-06-05-05  RPN Number entitled: " High-Dose Cyclophosphamide in the Treatment of Aggressive Multiple Sclerosis  ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 20
03-08-12-04 RPN Number entitled: " Management of Hepatitis C in HIV-Infected and Uninfected IDUs ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 150
03-10-17-01 RPN Number entitled: " Use of a Humanitarian Use Device for Treatment of Wide-Necked Cerebral Aneurysms ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 10
05-08-31-01 RPN Number entitled: " Use of the Humanitarian Use Device (HUD), Vertical Expandable Prosthetic Titanium Rib (VEPTR) ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 100
99-01-26-01 RPN Number entitled: " Treatment of HIV-related Tuberculosis Using a Rifabutin-Based Regimen (Closed to Accural) ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 15
NA_00002031 RPN Number entitled: " The WingspanTM Stent System and GatewayTM PTA Balloon, a Humanitarian Use Device ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 20
NA_00003217 RPN Number entitled: " Use of Contegra Pulmonary Valve Conduit Designated as Humanitarian Use Device November 21, 2003 Humanitarian Device Exemption (HDE) Number: H020003 ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 50
00-08-14-03 RPN Number entitled: " Ph. I/II Trial of Oxaliplatin as Neoadjuvant Treatment in Adults with Newly Diagnosed Glioblastoma Multiforme ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 12
00-12-28-06 RPN Number entitled: " Ph. I Trial of Samarium 153 in High Risk Osteogenic Sarcoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 18
02-015 RPN Number entitled: " Phase III Intergroup Trial of Adjuvant Chemoradition After Resection of Gastric or Gastroesophageal Adenocarcinoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 48
03-01-30-09 RPN Number entitled: " Expectant Management of Prostate Cancer with Curative Intent ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 1000
03-02-24-09 RPN Number entitled: " Phase II Study of High Dose Cyclophosphamide and Rituximab  in Low Grade and Mantle Cell Lymphoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 80
03-021 RPN Number entitled: " PhIII Rndmized Stdy Farnesyl Transferase Inhibitor R115777 in AML Pts in Second or Subsqunt Remiss After Primary Induct Failure or Patients over Age 60 in First Remission ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 35
03-06-10-05 RPN Number entitled: " Phase II, Study of Weekly Paclitaxel, Carboplatin and Irinotecan in Patients with advanced Non-Small Cell Lung Cancer and Malignant Pleural Effusion ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 45
03-09-08-02 RPN Number entitled: " High Dose Samarium-153 with Peripheral Blood Stem Cell Support in High Risk Osteogenic Sarcoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 30
03-09-22-14 RPN Number entitled: " Valproic Acid In the Induction of EBV Lytic Cycle Antigen Expression in Nasopharyngeal Carcinoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 22
03-09-22-15 RPN Number entitled: " Phase I/II Study of ABT-751 and Bevacizumab (Avastin)in  Combination with XELIRI (Capecitabine and Irinotecan) in Patients with Advanced Colorectal Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 44
03-12-15-04 RPN Number entitled: " HLA Matched Related and Unrelated Bone Marrow Transplantation with Busulfan/Cyclophosphamide and Post Transplantation Cyclophosphamide For Hematological Malignancies ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 60
04-001 RPN Number entitled: " Phase III Randomzied, Placebo Controlled, Trial of Docetaxel versus Docetaxel + ZD1839 in PS2 Patients or Previously-Treated patients with Recurrent or Metastatic Head and Neck Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 30
04-011 RPN Number entitled: " Randomized Phase III Trial Comparing 16 or 18 Weeks of Neoadjuvant Exemestane (25mg daily) Letrozole (2.5 mg) or Anastrozole (1mg)in Post-Menopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 140
04-012 RPN Number entitled: " A Double-Blind Randomized, Placebo Controlled Phase III Trial of Carboplatin, Paclitaxel, and BAY 43-9006 vs. Carboplatin, Paclitaxel and Placebo in Patients with Unresectable Locally Advanced or Stage IV Melanoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 48
04-015 RPN Number entitled: " A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0,I,or II Breast Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 10
04-017 RPN Number entitled: " A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 72
04-02-20-03 RPN Number entitled: " Ph.II Study in Operable Adenocarcinoma of the Esophagus to Measure Response Rate and Toxicity of Preoperative Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839 ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 36
04-03-22-01 RPN Number entitled: " A Phase I/II Partial Breast Irradiation with Concurrent Chemotherapy ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 40
04-03-25-02 RPN Number entitled: " Ph.II Study of Fixed Dose Capecitabine in Metastatic Breast Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 45
04-04-19-06 RPN Number entitled: " Phase I Trial of Arsenic Trioxide in the Treatment of Infiltrating Gliomas of Childhood  ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 7
04-05-13-01 RPN Number entitled: " Ph. II Study of Intensified CVP,  Rituximab and High Dose Cyclophosphamide for Adult Burkitt or Burkitt-Like Lymphoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 25
04-05-18-01 RPN Number entitled: " Evaluation of the Biological Effects of Broccoli Sprout Extract in Smokers ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 70
04-06-16-01 RPN Number entitled: " Phase II Clinical, Biological, and Pharmacological Study of Rapamycin (Rapamune, Sirolimus) in Patients with Advanced Pancreatic Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 50
04-07-27-04 RPN Number entitled: " Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Bone Marrow for Patients with Hematologic Malignances ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 100
04-07-31-01 RPN Number entitled: " A Randomized Phase III Trial of Irinotecan (CPT-11) and/or Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) after Curative Resection for Patients with Stage III Colon Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 60
04-08-04-02 RPN Number entitled: " Phase II Trial of Irinotecan in Metastatic Medullary Thyroid Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 20
04-08-09-04 RPN Number entitled: " Effect of Isoflavones on Cognition, Quality of Life and Hot Flashes in Men with Prostate Cancer Undergoing Androgen Deprivation Therapy ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 50
04-08-16-08 RPN Number entitled: " A Phase II Study to Assess the Ability of Neoadjuvant Chemotherapy +/- Second Look Surgery to Eliminate All Measurable Disease Prior to Radiotherapy for NGGCT ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 12
04-08-18-05 RPN Number entitled: " Ph.II Study of Cyclosporine A and Interferon to Induce Auto. GVHD Following 2-High Dose Chemo. Consolidation Regimens for Women with High-Risk Br. Ca. ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 80
04-08-26-05 RPN Number entitled: " A Phase I and Pharmacological Trial of 17-Allylamino-17 Demethoxygeldanamycin (17-AAG) and Cytarabine in Refractory Leukemia and Myelodysplastic Syndrome ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 20
04-09-02-05 RPN Number entitled: " A Phase II Study of Aerosolized GM-CSF in Patients with First Pulmonary Recurrent of Osteosaroma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 6
04-09-03-03 RPN Number entitled: " Phase I Trial with a Combination of Docetaxel + 153 Sm-EDTMP (Samarium 153) in Patients with Hormone-Refractory Prostate Cancer".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 12
04-09-15-04 RPN Number entitled: " Pilot Study of Adjuvant Therapy of Gefitinib (Iressa, ZD 1839) in Patients with Resectable Hepatocellular Carcinoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 4
05-015 RPN Number entitled: " Treatment of Children with Newly-Diagnosed Low Stage Lymphocyte Predominant Hodgkin Disease (LPHD). ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 25
05-019 RPN Number entitled: " Phase III Trial of Carboplatin and Paclitaxel Plus Placebo vs. Carboplatin and Paclitaxel Plus Concurrent Bevacizumab Followed by Placebo vs. Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, In Women with Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian or Primary Peritoneal Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 30
05-02-07-05 RPN Number entitled: " Pharmacokinetics, Biodistribution and Targeting of 111In-Labeled Humanized PAM4 IgG in Pre-Surgical Pancreatic Cancer Patients: An Examination of Protein Dose ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 19
05-02-11-03 RPN Number entitled: " A Safety and Efficacy Trial of Lethally Irradiated  Allogeneic Pancreatic Tumor Cells Transfected with the GM-CSF Gene in Combination with Erbitux (Cetuximab) for the Treatment of Advanced  Pancreatic Adenocarcinoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 60
05-02-16-03 RPN Number entitled: " LCH III Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 36
05-02-23-01 RPN Number entitled: " Phase I Dose Escalation Trial of Raf Kinase Inhibitor BAY 43-9006 as Single Agent for Adult with Relapsed and Refractory Acute Leukemias and Chronic Myeloid Leukemia in Blast Crisis ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 48
05-023 RPN Number entitled: " Ph III Study for the Tx of Children& Adolescents w/Newly Diagnosed Low-Risk HD".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 15
05-03-30-06 RPN Number entitled: " Phase II Study of Initial Treatment with Methotrexate in Large Granular Lymphocytic (LGL) Leukemia ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 10
05-04-04-03 RPN Number entitled: " Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Myco0phenolate Mofetil (MMF), Denileukin Diftitox (Ontak), and Pentostatin in Combination with Corticosteroids ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 30
05-04-14-02 RPN Number entitled: " A Feasibility Study for Individulalized Treatment of Advanced Pancreatic Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 40
05-05-03-01 RPN Number entitled: " Phase I Trial of Tailored Radiation Therapy with Concomitant Cetuximab and Cisplatin in the Treatment of Patients with Cervical Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 9
05-05-04-02 RPN Number entitled: " A Dose Escalating Phase I Study with an Expanded Cohort to Assess the Feasibility of Intraperitoneal Carboplatin and Intravenous Paclitaxel in Patients with Previously Untreated Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma  ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 8
05-05-10-02 RPN Number entitled: " Phase II, Evaluation of Weekly Topotecan Hydrochloride (Hycamtin, NSC609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (Group A) ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 8
05-05-16-04 RPN Number entitled: " High Risk B-Precursor Acute Lymphoblastic Leukemia ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 4
05-05-16-07 RPN Number entitled: " Phase I/II Study of Rituximab, High Dose Cyclophosphamide, and GM-CSF Based Immunotherapy for Relapsed Hodgkin's Lymphoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 20
05-06-08-02 RPN Number entitled: " HLH-2004 Hemophagocytic Lymphohistiocytosis Study Group Treatment Protocol of the Second International HLH Study 2004 ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 12
05-06-21-03 RPN Number entitled: " Ph.I Trial of Intravenous Paclitaxel Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Docetaxel, Intraperitoneal Carboplatin, and Intraperitoneal Paclitaxel in Patients with Previously Untreated Epithelial Ovarian Carcinoma, Fallopian Tube or Primary Peritoneal Carcinoma  ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 8
05-08-04-08 RPN Number entitled: " Phase II Study of Erlotinib Combined with Chemoradiation and Adjuvant Chemotherapy in Patients with Resectable Pancreatic Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 60
05-08-17-03 RPN Number entitled: " A Phase II Study of Liposomal Doxorubicin (Lipo-Dox) in Patients with Brain Metastasis from Breast Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 5
05-09-01-04 RPN Number entitled: " Phase II Study of Neo-adjuvant Chemotherapy for Locally Advanced Gastric Cancer".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 3
20000506 RPN Number entitled: " Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 10
20020764 RPN Number entitled: " Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small Cell Lung Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 60
20021712 RPN Number entitled: " Ph. II Randomized, Cross-Over, Double-Blinded, Placebo Controlled Trial of the Farnesytransferase Inhibitor R115777 in Pediatric Patients with Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 6
20030120 RPN Number entitled: " A Phase I/II Trial of BMS-247550 for Treatment of Patients with Recurrent High-Grade Gliomas ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 5
20030198 RPN Number entitled: " Phase III Group-Wide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents with Newly Diagnosed Intermediate Risk Hodgkin Disease ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 15
20030338 RPN Number entitled: " Perinatal Neuroblastoma: Expectant Observation. A Children's Oncology Group Pilot Study ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 5
20030624 RPN Number entitled: " A Randomized Phase II Chemopreventive Study of Iloprost Versus Placebo in Patients at High Risk for Lung Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 20
20031619 RPN Number entitled: " Ph. III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 20
20031757 RPN Number entitled: " A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence with Standard Chemotherapy to Patients with Relapsed Acute Myeloid Leukemia Expressing FLT-3 Activating Mutations ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 20
20031758 RPN Number entitled: " A Ph. II/III Study  of Immunomodulation after High Dose Myeloablative Therapy with Autologous Stem Cell Rescue for Refractory/Relapsed Hodgkin Disease  ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 16
20040025 RPN Number entitled: " Randomized Ph. III Trial of Doxorubicin/ Cisplatin/Paclitaxel and G-CSF vs. Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 10
20040348 RPN Number entitled: " A Ph. II Evaluation of Irofulven in the Treatment of Recurrent or Persistent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 3
20040422 RPN Number entitled: " Pharmacokinetic Study of Methotrexate Using an Intratumoral Microdialysis Catheter  ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 3
20040514 RPN Number entitled: " Phase I/II, Open-Label, Non-Randomized, Multicenter, Single Agent Study of Intravenous SDX-102 for the Treatment of Patients with MTAP-Deficient High Grade Recurrent Malignant Gliomas ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 6
20040626 RPN Number entitled: " Treatment of Newly Diagnosed Childhood Acute Myeloid Leukemia (AML)Using Intensive MRC-Based Therapy and Gemtuzumab Ozogamicin (GMTZ): A COG Pilot Study ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 5
20040629 RPN Number entitled: " Randomized Ph. III Trial Comparing Two Different Rituximab Dosing Regimens for Patients with Low Tumor Burden Indolent Non-Hodgkin's Lymphoma  ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 24
20040760 RPN Number entitled: " Phase II Study of Anti-CD20 Monoclonal Antibody (Rituximab) Therapy for Patients with Refractory or Relapsed Primary Central Nervous System Lymphoma (PCNSL) ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 5
20040941 RPN Number entitled: " A Randomized Phase II Study: Sequencing Topoisomerase Inhibitors for Extensive Stage Small Cell Lung Cancer(SCLC): Topotecan Squenced with Etoposide/Cisplatin, and Irinotecan/Cisplatin Sequenced with Etoposide ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 10
20041061 RPN Number entitled: " An Open-Label Extended- Use Study of Oral CEP-701 in Patients with Hematologic Malignancies Who Have Participated in a Clinical Study of CEP-701 ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 30
20041158 RPN Number entitled: " A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A 0201-Positive Patients with Previously Treated Uresectable Stage III or IV Melanoma  ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 25
20041175 RPN Number entitled: " A Double-Blind, Randomized, Placebo-Controlled, Phase II Study of Recombinant Human Lactoferrin as Prophylaxis for Chemotherapy-Induced Mucositis and Neutropenic Fever in Acute Myelogenous Leukemia Patients  ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 40
20041597 RPN Number entitled: " A Phase II Open Label, Multiple-Dose Study of Intracavitary Administered 131 1-TM-601 in Adult Patients with Recurrent High Grade Glioma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 9
20050048 RPN Number entitled: " Ph. II Trial of PTK787/ZK222584 in Patients with Advanced or Metastatic Pancreatic Adenocarcinoma who Failed First-Line Gemcitabine Therapy ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 36
20050456 RPN Number entitled: " A Prospective, Randomized, Double-Blind Active Controlled Parallel Group Multi-Center Trial to Assess the Efficacy and Safety of Mycophenolate Mofetil (MMF) in Inducing Response and Maintaining Remission in Subjects with Lupus Nephritis ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 10
20051458 RPN Number entitled: " A Phase I, Open-Label Multi-Center, Dose Escalation Study of the Safety and Pharacokinetics of AGS-PSCA Given as Monotherapy in Subjects with Advance Prostate Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 10
20051673 RPN Number entitled: " Phase I Study of Erbitux (Cetuximab) in Pediatric Subjects with Refractory Solid Tumors: Charaterization of Serum Pharmacokinetics, Safety, and Efficacy of Cetuximab when Combined with Irinotecan ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 7
20052031 RPN Number entitled: " A Continuation Clinical Trial of Oral L-001079038 in Advanced Cancers ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 2
20052048 RPN Number entitled: " A Phase I Study of Chimeric Antibody Against Interleukin-6 (CNTO 328) Combined with Docetaxel in Subjects with Metastatic Hormone-Refractory Prostate Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 4
20052193 RPN Number entitled: " A Randomized Study of Intermittent Capecitabline in Combination with Oxaliplatin and Bevacizumab vs. Intermittent Capecitabine in Combination with Oxaliplatin and Bevacizumab as First Line Treatment for Patients with Metastatic Coloretal Cancer".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 204
20052203 RPN Number entitled: " Phase I/II Clinical Trial of Oral Vorinostat (MK-0683) in Combination with Erlotinib in Patients with Relapsed/ Refractory Non-Small Cell Lung Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 16
20052342 RPN Number entitled: " Phase I, Randomized, Multicenter, Double Blinded Study of MK-0429 in the Treatment of Men with Hormone Refractory Prostate Cancer and Metastatic Bone Disease ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 6
20052474 RPN Number entitled: " A Phase I Study of Oral PHA-848125AC Given Daily for 7 Consecutive Days Every 2 Weeks or for 4 Consecutive Days a Week for 3 Consecutive Weeks Every 4 Weeks to Adult Patients with Advanced Metastatic Solid Tumors ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 20
20052638 RPN Number entitled: " Phase I Dose-Escalation Study of LY-2157299 in Patients with Advanced or Metastatic Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 18
20052688 RPN Number entitled: " Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB007839 Following Multiple Oral Doses in Patients with Solid Tumors ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 10
20060163 RPN Number entitled: " Phase I Dose-Escalation Study of Seneca Valley Virus (SVV-001), a Replication Competent Picornavirus, in Patients with Advanced Solid Tumors with Neuroendocrine Features ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 12
20060768 RPN Number entitled: " Evaluation of OraTest in Combination with Visual Examination in the Improved Detection of Oral Mucosal Lesions Suspicious of Serious Pathology in High-Risk Patients for the Purpose of Referral to the Health Care Professional Experienced in Oral Cancer... ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 400
20060814 RPN Number entitled: " A Study of the Efficacy of MORab-003 in Subjects with Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 7
20060905 RPN Number entitled: " A Phase I Dose Escalation Study of BMS 641988 in Patients with Castration-Resistant Prostate Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 15
20060991 RPN Number entitled: " Open Label Dose Escalation Ph. I Trial of MK-0646 Given as a One to Two Hour Every  Other Week Infusion in Patients with Relapsed or Refractory Locally Advanced or Metastatic Cancers ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 12
20061214 RPN Number entitled: " A Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 50
20061225 RPN Number entitled: " Phase I Trial of Gemcitabine (Gemzar) + ABI-007 (Abraxane) in Patients with Advanced Metastatic Pancreatic Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 12
20061317 RPN Number entitled: " Phase I/II Study in Subjects with Locally Advanced, Recurrent or Metastatic Hepatocellular Carcinoma, Evaluating the Safety, Pharmacokinetics, and Anti Tumor Activity of ADH300004 (eniluracil) with Escalating Doses of 5-Fluorouracil Administered Orally Once Weekly for 3 Weeks out of Every 4  ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 10
20061324 RPN Number entitled: " Open-Label, Multi-Center Study of the Efficacy and Safety of MCC in the Treatment of Patients with Non-Muscle Invasive (Superficial) Bladder Cancer at High Risk of Progression and Who are Refractory to BCG ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 5
20061407 RPN Number entitled: " A Phase 1 Open-label, Dose-escalation, Safety and Pharmacokinetic Study of MDX 1106 in Patients with Selected Refractory or Relapsed Malignancies ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 20
20061559 RPN Number entitled: " Defibrotide for the Treatment of Severe Hepatic Veno-Occulsive Disease in Hematopoietic Stem Cell Transplant Patients ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 17
20061791 RPN Number entitled: " Ph.I Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability an Maximum Tolerated Dose of Daily Oral Administration of AV-412 in Patients with Refractory or Relapsed Solid Tumor Malignancies ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 25
20061960 RPN Number entitled: " A Phase I/IIa Study Evaluating the Safety, Pharmacokinetics, Efficacy of ABT-263 in Subjects with Small Cell Lung Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 10
20062147 RPN Number entitled: " PHI Dose Escalation Study to Examine the Safety and Tolerability of IC83 Administered 1 Day after Pemetrexed 500 mg/m2 Every 21 Days in Patients with Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 25
20062160 RPN Number entitled: " An Open Label Ph I/II Study of XIAP Antisense AEG35156 Administered to Patients with Refractory/Relapsed AML in Combination with Chemotherapy ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 20
20062406 RPN Number entitled: " A Phase II Open Label Study of Brivanib (BMS-582664), Administered Orally at A Dose of 800 mg Daily in Subjects with Unreseactble, Locally Advanced or Metastatic Hepatolcellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 4
20070055 RPN Number entitled: " Phase I S-TRANS, TRANS-FARNESYLTHIOSALICYLIC ACID Administrated on Days 1 to 21 of a 28 Cycle in Combination with Gemcitabine in Pts w/Adv Biliary Tract & Pancreatic Cancer".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 12
20070424 RPN Number entitled: " Phase III International, Randomized, Double-Blind, Parallel-Group, Multi-Centre Study to Assess the Efficacy of ZD6474(ZACTIMA)Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients with Locally Advanced or Metastatic (Stage IIB-IV)  Non-Small Cell Lung Cancer (NSCLC) after Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 8
90-01-26-05 RPN Number entitled: " Use of Erwinia L-Asparaginase in Pediatric Cancer Patients ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 30
99-12-03-01 RPN Number entitled: " High-Dose Cyclophosphamide for the Treatment of Myasthenia Gravis and other Autoimmune Neuromuscular Disorders".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 35
AALL0331 RPN Number entitled: " Standard Risk B-Precusor Acute Lymphoblastic Leukemia ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 32
AALL0433 RPN Number entitled: " Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 10
AALL0434 RPN Number entitled: " Intensified Methotrexate, Nelarabine (Compound 506U78; IND# 52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 24
AAML0431 RPN Number entitled: " The Treatment of Down Syndrome Children with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Under the Age of 4 Years ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 8
AAML06P1 RPN Number entitled: " A Pilot Study of Lestaurtinib (CEP-701) in Combination with Chemotherapy in Young Patients with Relapsed or Refractory FLT3-mutant Acute Myeloid Leukemia ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 4
AOST0331 RPN Number entitled: " Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-Operative Chemotherapy ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 20
ARAR0331 RPN Number entitled: " Treatment of Childhood Nasopharyngeal Carcinoma with Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 8
AREN0532 RPN Number entitled: " Treatment for Very Low, Low and Standard Risk Favorable Histology Wilms Tumor ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 25
ARET0332 RPN Number entitled: " A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 20
ARST0332 RPN Number entitled: " Risk-Based Treatment of Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas-- Groupwide Phase III Study ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 25
ARST0431 RPN Number entitled: " Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients with High-Risk Rhabdomyosarcoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 6
ARST0531 RPN Number entitled: " Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk

Rhabdomyosarcoma (RMS) ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 10
ASCT0431 RPN Number entitled: " A Randomized Trial of Sirolimus-Based Graft versus Host Disease (GVHD) Prophylaxis after Hematopoietic Stem Cell Transplantation (HSCT) in Relapsed Acute Lymphoblastic Leukemia (ALL) ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 20
COG-AAML0531 RPN Number entitled: " Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 18
COG-AHOD0521 RPN Number entitled: " A Phase II Study of Bortezomib (Velcade, PS-341, IND # 58443) in Combination with Ifosfamide/Vinorelbine in Pediatric Patients and Young Adults with

Refractory/Recurrent Hodgkin Disease ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 6
COG-AREN0321 RPN Number entitled: " Treatment of High Risk Renal Tumors ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 8
COG-AREN0533 RPN Number entitled: " Treatment for Newly Diagnosed Higher Risk Favorable Histology Wilms Tumor ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 10
COGAAML0523 RPN Number entitled: " A Phase I/II Study of CLOLAR™ (Clofarabine, IND# 73,789) in Combination with Cytarabine in Pediatric Patients with Refractory/Relapsed Leukemia ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 8
EPACCT1 RPN Number entitled: " Program for the Assessment of Clinical Cancer Tests (PACCT-1) Trial Assigning Individualized Options for Treatment: The TAILORx Trial ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 30
NA00000544 RPN Number entitled: " A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 Gy and Chemotherapy In Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 10
NA00000845 RPN Number entitled: " Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Adults with Relapsed or Refractory Acute Leukemias ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 70
NA00000875 RPN Number entitled: " A Phase II Evaluation Of Gemcitabine (NSC #613327) And Docetaxel (NSC #628503) In The Treatment Of Recurrent Or Persistent Carcinosarcoma Of The Uterus ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 6
NA00000891 RPN Number entitled: " A Multi-Center Phase Ib Study of Oxaliplatin in Combination with Fluorouracil and Leucovorin in Pediatric Patients with Advanced Solid Tumors ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 6
NA00000901 RPN Number entitled: " Cyclophosphamide plus Transplantation of Partially HLA-Mismatched (Haploidentical), CD8+ T Cell-Depleted Peripheral Blood Cells (PBCs) for Patients with Myelodysplastic syndrome(MDS), refractory acute myeloid leukemia (AML) or Myeloproliferative Disorders (MPD) ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 44
NA00000909 RPN Number entitled: " A Multi-Center Rand-omized Clinical Trial Correlating the Effects of 24 Months of Exemestane or Letrozole on Surrogate Markers of Response with Aromatase Polymorphism ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 180
NA00000920 RPN Number entitled: " Ex vivo Expansion of Mafosfamide Purged CD34+ cells in Patients with Acute Leukemia ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 20
NA00000959 RPN Number entitled: " A Randomized Phase II Trial of Multi-Epitope Vaccination with Melanoma Peptides for Cytotoxic T-Cells and Helper T-Cells for Patients with Metastatic Melanoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 24
NA00001011 RPN Number entitled: " A Pharmacodynamic Study of Pre-Prostatectomy Rapamycin in Men with Advanced Localized Prostate Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 35
NA00001107 RPN Number entitled: " Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination with the VEGF Inhibitor Bevacizumab in Patients with Metastatic Renal Cell Carcinoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 42
NA00001108 RPN Number entitled: " Clinical Trial Comparing Pre-Oper Rad Therapy & Capcetabine with or w/o Oxaliplatin with Pre-Operative Radiation Therapy and Continuous Infusion of 5FU with or w/o Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 80
NA00001201 RPN Number entitled: " Determination of the In-Tumor-Concentration of Imatinib Mesylate in Malignant Glioma after Oral Administration ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 33
NA00001232 RPN Number entitled: " Phase I Safety Study of Clostridium novyi-NT Spores in Patients with Treatment Refractory Solid Tumor Malignancies ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 20
NA00001249 RPN Number entitled: " Phase II Trial of Bevacizumab with Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 30
NA00001294 RPN Number entitled: " A Phase II Study of Cetuximab in Combination with External Beam Radiation Followed by Consolidation Chemotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 10
NA00001390 RPN Number entitled: "Psychopharmacology of Psilocybin in Cancer Patients".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 44
NA00001428 RPN Number entitled: "Effect of Nightly vs. prn Sildenafil use on Early Return of Erectile Function Following Nerve-Sparing Laparoscopic Radical Prostatectomy".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 100
NA00001530 RPN Number entitled: "K562/GM-CSF Vaccination in Patients with Myelodysplastic Syndrome".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 30
NA00001547 RPN Number entitled: "A quality of life comparison in patients with malignant dysphagia treated with either self-expanding plastic stents (SEPS) or self-expanding metal stents (SEMS)".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 80
NA00001661 RPN Number entitled: "A Randomized, Ph II/III Study of TNferade Biologic with 5-FU And Radition Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 12
NA00001757 RPN Number entitled: "Phase II Study of a Single-Agent Cetuximab for Treatment of High-Risk Pre-Malignant Upper Aerodigestive Lesions".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 20
NA00001801 RPN Number entitled: "A Feasibility Study of Combination Therapy with Trastuzumab, Cyclophosphamide and an Allogeneic GM-CSF Secreting Breast Tumor Vaccine for the Treatment of HER-2/neu-Overexpressing Metastatic Breast Cancer".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 20
NA00001887 RPN Number entitled: "A Randomized Phase II Trial of Interferon + GM-CSF versus K562/GM-CSF Vaccination in CML Patients Achieving a Complete Cytogenetic Response to Imatinib".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 56
NA00001903 RPN Number entitled: " Transplantation of Expanded and Unexpanded Umbilical Cord Blood Units Following Myeloablative Chemotherapy for Hematologic Malignancies ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 40
NA00001957 RPN Number entitled: " A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for T2uNO Rectal Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 40
NA00001962 RPN Number entitled: " A Multicenter, Open Label, Randomized, Ph IIIComparing Immediate Adj Hormonal Therapy in Combo w/Taxotere Admin Every 3Wks vs. Hormonal Therapy Alone vs. Deferred Therapy Followed by the Same Therapeutic Options in Pts w/Prostate Ca at High Risk of Relapse After Radical Prostatectomy ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 20
NA00002002 RPN Number entitled: " Phase II Study of Mitomycin-C in Patients with Advanced or Recurrent Pancreatic Cancer with Mutated BRCA2 Gene ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 38
NA00002033 RPN Number entitled: " Phase I/II Study of PDX101 in Patients with Unresectable Hepatocellular Carcinoma with Pharmacokinetic and Pharmacodynamic Evaluation ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 8
NA00002178 RPN Number entitled: " A Pilot Study of Differentiation Therapy in Multiple Myeloma Using Interleukin-6 and Interferon-a ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 35
NA00002394 RPN Number entitled: " Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy with Active Breathing Coordinator   ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 50
NA00002408 RPN Number entitled: " A Phase I, Open-Label, Single Injection, Dose Escalation Study of the Safety and Tolerability Following Intravenous Administration of CRS-100 to Adult Subjects with Carcinoma and Liver Metastases ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 36
NA00002473 RPN Number entitled: " Phase II trial of Rituximab-ABVD for Classical Hodgkin's Lymphoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 20
NA00002479 RPN Number entitled: " A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Paritally HLA-Mismatched Bone Marrow for Patients with Sickle Cell ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 25
NA00002488 RPN Number entitled: " Pemetrexed Plus Gemcitabine or Carboplatin in Patients with Advanced Malignant Mesothelioma: A Randomized Phase II Trial ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 22
NA00002578 RPN Number entitled: " K562/GM-CSF Vaccination in Combination with Imatinib Mesylate as Booster for Chronic Myeloid Leukemia Patients Previously Vaccinated on Protocol J0345 ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 19
NA00002731 RPN Number entitled: " A Safety and Efficacy Trial of Vaccine Boosting with Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected with the GM-CSF Gene for the Treatment of Pancreatic Adenocarcinoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 30
NA00003034 RPN Number entitled: " Phase II Trial of Triapine (IND #68338, NSC #663249, 3-aminopyridine-2-carboxaldehyde thiosemicarbone) plus Fludarabine (NSC #312887, fludarabine monophosphate) in Adults with Aggressive Myeloproliferative Disorders (MPDs) ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 35
NA00003067 RPN Number entitled: " Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341 (VELCADE) in Comination with Irinotecan or PS-341 Alone Followed by the Addition of Irinotecan at Time of Progression in Patients with Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 9
NA00003073 RPN Number entitled: " Sequential Administration of Cryoablation and Cyclophosphamide for Advanced Epithelial Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 15
NA00003076 RPN Number entitled: " Phase II Study of Bexarotene + Sargromastatin as Agents of Differentiation in MDS and AML ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 18
NA00003111 RPN Number entitled: " Multicenter Selective Lymphadenectomy Trial II: A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 50
NA00003114 RPN Number entitled: " A Phase I/II Study of MS 275 in Combination with 5-azacytidine in Patients with Recurrent Advanced Non-Small Cell Lung Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 36
NA00003123 RPN Number entitled: " Posttransplant Immunotherapy Using Donor Lymphocyte Infusions with Autologous Tumor Vaccines Following HLA Related Bone Marrow Transplantation or Hematologic Malignancies ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 35
NA00003125 RPN Number entitled: " A randomized controlled comparative trial to determine if testosterone gel prevents steroid related weakness in brain cancer patients ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 60
NA00003256 RPN Number entitled: " High Dose Cyclophosphamide in Steroid Refractory Acute Graft Versus Host Disease ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 35
NA00003375 RPN Number entitled: " Phase I Study of Alefacept (Amevive) in Treatment of Cutaneous T-Cell Lymphoma and Peripheral T-Cell NHL ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 8
NA00003461 RPN Number entitled: " A Multi-Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin with Radiation Therapy in Patients with Pancreatic Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 18
NA00003507 RPN Number entitled: " Open Label Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid in Subjects with Recurrent High Grade Glioma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 8
NA00003621 RPN Number entitled: " ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 60
NA00004008 RPN Number entitled: " Therasphere for the Treatment of Liver Metastases: Open Label Trial of Therasphere in Patients with Liver Metastases from Primary Colorectal Cancer, Neuroendocrine Cancer or Non-Colorectal/Non-Neuroendocrine Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 30
NA00004034 RPN Number entitled: " Response-Adapted Therapy for Aggressive non-Hodgkin's Lymphomas based on early [18F] FDG-PET Scanning ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 24
NA00004193 RPN Number entitled: " Phase III Rituxan/BEAM vs. Bexxar/BEAM with Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-cell Non-Hodgkin’s Lymphoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 6
NA00004377 RPN Number entitled: " Phase II Study of Alvocidib (NSC 649890, IND 46,211) in Timed Sequential Combination with Cytosine Arabinoside (ara-C) and Mitoxantrone for Adults with Newly Diagnosed, Previously Untreated, Poor-Risk Acute Myelogenous Leukemias ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 35
NA00004453 RPN Number entitled: " A Phase II Study of Cyclosporine in the Treatment of Angioimmunoblastic T-Cell Lymphoma".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 5
NA00004584 RPN Number entitled: " Phase I/II Study of a Combination of Suberoylanilide Hydroxyamic Acid (vorinostat) + Paclitaxel and Bevacizumab in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent Breast Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 10
NA00004803 RPN Number entitled: " Phase II Trial of Sorafenib (BAY43-9006) (IND69896; NSC 724772) in Patients with Advanced Urothelial Cancer  ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 6
NA00004943 RPN Number entitled: " Phase 1 Safety Evaluation of Oral Enzastaurin in Combination with Bevacizumab in Patients with Advanced/Metastatic Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 42
NA00004964 RPN Number entitled: " A Pharmacokinetic and Pharmacogenomic Study of Patients with High-Grade Gliomas Receiving Daily Radiation Therapy and Temozolomide ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 50
NA00005595 RPN Number entitled: " A Phase II Study of MOAD (Methotrexate, Vincristine, L-asparaginase and Dexamethasone) with Subcutaneous Campath (NSC 715969) for Adults with Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 10
NA00005627 RPN Number entitled: " A Multicenter, Open-Label, Single Agent, Two Stage Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects with Advanced Malignant Glioma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 6
NA00005743 RPN Number entitled: " A Phase I/II Study of 131I-Tositumomab in Patients with Relapsed/Refractory Hodgkin’s Lymphoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 30
NA00005863 RPN Number entitled: " Phase I, Open-label, Multi-center, Dose-Escalation Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD7762 Administered as a Single Intravenous Agent and in Combination with Weekly Standard Dose Gemcitabine in Patients with Advanced Solid Malignancies ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 25
NA00005967 RPN Number entitled: " A Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination with Trastuzumab (Herceptin) in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent Her-2 Amplified Breast Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 7
NA00006008 RPN Number entitled: " Revlimid to Augment Efficacy of Prevnar Vaccines in Patients with Relapsed or Refractory Myeloma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 40
NA00006188 RPN Number entitled: " CHAARTED: ChemoHormonal Therapy vs. Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 40
NA00006237 RPN Number entitled: " A Randomized Phase II Trial of Azacitidine With or Without the Histone Deacetylase Inhibitor MS-275 for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (dysplastic type), and Acute Myeloid Leukemia with Multilineage ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 45
NA00006855 RPN Number entitled: " A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients with Recurrent Glioblastoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 13
NA00006989 RPN Number entitled: " A Phase II Study of an Oral Histone Deacetylase Inhibitor, MS-275 in Combination with Sargramostim Treating MDS or Relapsed and Refractory Myeloid Malignancies ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 18
NA00007020 RPN Number entitled: " A Randomized Phase II Study of Docetaxel +/- ZD6474 (Zactima) in Metastatic Transitional Cell Carcinoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 12
NA00007285 RPN Number entitled: " Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children and Young Adults with Relapsed or Refractory Acute Leukemias ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 10
NA00007477 RPN Number entitled: " A Phase I, Open Label Study of AT-101 Plus Radiotherapy and Temozolomide and of AT-101 Plus Adjuvant Temozolomide for Patients with Newly-Diagnosed Glioblastoma Multiforme ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 5
NA00007517 RPN Number entitled: " Phase II Study of Dasatinib (BMS-354825) for Androgen-Deprived Progressive Prostate Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 8
NA00007596 RPN Number entitled: " Phase I Study of a Pharmacologically Derived Hybrid Bolus-Infusion Schedule of Flavopiridol (NSC 64890, IND 46,211) Given in Timed Sequential Combination with Cytosine Arabinioside (ara-C) and Mitoxantrone for Adults with Relapsed and Refractory Acute Leukemias ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 36
NA00007667 RPN Number entitled: " Open-Label, Ph.I Study of Systemic Hedgehog Pathway Antagonist, GDC0449, In Patients with Locally Advanced or Metastatic Solid Tumors that are Refractory to Standard Therapy or For Whom no Standard Therapy Exists ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 10
NA00007682 RPN Number entitled: " A Phase III, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Zometa for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 40
NA00007736 RPN Number entitled: " A Randomized, Open Label, Multi-Center Study of XRP6258 At 25 mg/m2 in Combination With Prednisone Every 3 Weeks Compared to Mitoxantrone in Combination With Prednisone For the Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated With A Taxotere Containing Regimen ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 12
NA00007920 RPN Number entitled: " KGEL Vaccine After Initial Therapy of Hodgkin's Lymphoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 20
NA00008770 RPN Number entitled: " Phase II Study of Rituximab Given in Conjunction w/Standard Chemotherapy in Primary CNS Lymphoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 14
NA00008914 RPN Number entitled: " Feasibility Pilot and Phase 2 Study of Chemoimmunotherapy with Epratuzumab for Children with Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL) ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 6
NA00009071 RPN Number entitled: " Radiotherapy alone versus chemotherapy followed by response-based radiotherapy for newly diagnosed primary CNS germinoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 5
NA00009089 RPN Number entitled: " A Phase I Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Weekly Administration of GRN163L in Patients with Refractory or Relapsed Multiple Myeloma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 6
NA00009108 RPN Number entitled: " Bevacizumab and CHOP (A-CHOP) in Combination for Patients with Peripheral T-Cell or Natural Killer Cell Neoplasms  ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 7
NA00009257 RPN Number entitled: "  A Phase Ib, Open Label, Multi-Center Trial of Intravenous INO-1001 plus oral Temozolomide to Evaluate the Tolerability, Safety, and Pharmacokinetics in Subjects with Newly-Diagnosed or Recurrent Unresectable Stage III or Stage IV Melanoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 10
NA00009309 RPN Number entitled: " A Phase II/III Randomized, Double-Blind Study of Paclitaxel plus arboplatin in Combination with Vorinostat (MK-0683) or Placebo in Patients with Stage IIIB (with pleural effusion) or Stage IV Non-Small-Cell Lung Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 10
NA00009558 RPN Number entitled: " A Phase I Open-Label Dose-Finding Study of Intravenous BI 2536 BS ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 10
NA00009695 RPN Number entitled: " An Open-Label Study to Determine the Maximum Tolerated Oral Dose of the Kinase Inhibitor CEP-11981 in Patients With Advanced Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 25
NA00009699 RPN Number entitled: " A PhaseI/II, Open-label, Dose Escalation, trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of RAF265 (CHIR-265) Administered Orally to Patients with Locally Advanced or Metastatic Melanoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 15
NA00009745 RPN Number entitled: " Pilot Trial of Intraperitoneal Paclitaxel and Carboplatin with IV Avastin Therapy in Treatment of Women with Newly Diagnosed, Optimally Cytoreduced Carcinoma of Mullerian Origin ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 12
NA00009758 RPN Number entitled: " A Phase 2 Study of Temozolomide (SCH 52365) in Subjects with Advanced Aerodigestive Tract Cancers Selected for Methylation of O6 Methyl-Guanine-DNA Methyltransferase (MGMT) Promoter ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 12
NA00009786 RPN Number entitled: " A Phase 1, Open-Label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of MGCD0103 (MG-0103) in Combination with Docetaxel (Taxotere) in Subjects with Advanced Solid Malignancies ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 20
NA00009867 RPN Number entitled: " Phase III, MC, Rand Placebo-Controlled Trial Evaluating the Efficacy and Safety of Bevaizumab in Combination with Chemotherapy Regimens in Subjects with Previously Treated Metastatic Breast Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 7
NA00010061 RPN Number entitled: " Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 12
NA00010089 RPN Number entitled: " Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute, Non-infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 2
NA00010901 RPN Number entitled: " A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination with Tarceva™ (erlotinib) Compared with Tarceva™ Alone for Treatment of Advanced Non-Small Cell Lung Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 10
NA00010928 RPN Number entitled: " A Phase I Investigation of the Intravenous Administration of MK-4721 in Patients with Advanced Hormone Refractory Prostate Cancer ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 15
NA00011438 RPN Number entitled: " Phase 1b Open-label, Multicenter, Dose-Escalating, Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of SNS 595 Injection in Combination with Cytarabine in Patients with Relapsed or Refractory Acute Myeloid Leukemia ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 25
NA00011464 RPN Number entitled: " A Phase 1 Study of ABT-888 in Combination with Topotecan plus Carboplatin for Relapsed and Refractory Acute Leukemias and High-Risk Myelodyplasias and Myeloproliferative Disorders ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 48
NA00011479 RPN Number entitled: " A Phase II Evaluation of CCI-779 (Temsirolimus, NCI-Supplied Agent, NSC#683864, IND#61010) In The Treatment Of Persistent Or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 7
NA00011515 RPN Number entitled: " A Phase II Trial of Dasatinib in Advanced Sarcoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 20
NA00011650 RPN Number entitled: " Phase II Study of 2 Methoxyestradiol Nanocrystal Colloidal Dispersion (Panzem®) Alone and in Combination with Sunitinib Malate in Patients with Metastatic Renal Cell Carcinoma Progressing on Sunitinib Malate ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 26
NA00012030 RPN Number entitled: " Phase 1, Open-Label, Dose-Escalation, Multiple Dose Study of the Safety, Tolerability and Immune Response of CRS-207 in Adults Subjects with Selected Advanced Solid Tumors Who Have Failed or Who are not candidates for Standard Treatment  ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 10
NA00012038 RPN Number entitled: " Adoptive Immunotherapy Utilizing Activated Marrow Infiltrating Lymphocytes in the Autologous Transplant Setting in Multiple Myeloma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 15
NA00012129 RPN Number entitled: " Phase I Trial of Highly Conformal Radiation Therapy For Patients With Liver Metastases ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 5
NA00012616 RPN Number entitled: " A Phase I Trial of 5Azacitidine and Suberoylanilide hydroxamic acid in Patients with Metastatic or Locally Recurrent Nasopharyngeal Carcinoma and Nasal NK-T cell Lymphoma  ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 4
NA00013105 RPN Number entitled: " A Phase I/II Multi-Institutional Double Blinded Randomized Study to Determine the Tolerability ad Efficacy of 2 Different Doses of Revlimid (CC-5013, Lenalidomide) in Biochemically Relapsed Prostate Cancer Patients (M0) after Local Treatment ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 60
NA00014041 RPN Number entitled: " A Randomized Phase II Trial of Tipifarnib (R115777, ZARNESTRA, NSC #702818, IND #58,359) in Combination with Oral Etoposide (VP-16) in Elderly Adults with Newly Diagnosed, Previously Untreated Acute Myelogenous Leukemia (AML ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 40
NA_00010794 RPN Number entitled: " A Phase I/II Safety and Exploratory Pharmacodynamic Study of Intravenous Temsirolimus (CCI-779) in Pediatric Subjects with Relapsed/Refractory Solid Tumors ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 8
NA_00011878 RPN Number entitled: " A Phase II Evaluation of Trabectedin (Yondelis, R279741, IND#75,111) In The Treatment Of Advanced, Persistent or Recurrent Uterine Leiomyosarcomas ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 3
NA_00014566 RPN Number entitled: " Phase II Study of Ifosphamide and Doxorubicin in Patients with Refractory Nasopharyngeal Carcinoma ".  Approved by the Johns Hopkins Medicine Institutional Review Board.  Number of subjects who may be enrolled at Hopkins: 35


© Copyright 2000 | All Rights Reserved | Johns Hopkins University
School of Medicine
720 Rutland Avenue, Baltimore, Maryland 21205 USA

 

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

U.S. 1-410-464-6713 (toll free)
International +1-410-614-6424

 

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer